2020

1. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies

   Annals of Oncology, Vol. 31, Núm. 9, pp. 1186-1197

2. The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407)

   Oncologist, Vol. 25, Núm. 9, pp. 745-e1265